Login to Your Account


Carries on in lymphedema

A Japanese cancer drug that Eiger Biopharmaceuticals Inc. hoped would help key subgroups of people with PAH failed to do so, missing both the primary and a key secondary endpoint of the phase II study, Liberty. more »


Our Habitat for All Things Science
Cholesterol precursor 'trains' innate immunity
Opinion


Partners in Focus